Jove
Visualize
Contact Us

Related Experiment Videos

Waldenström's macroglobulinemia.

M A Dimopoulos1, E Galani, C Matsouka

  • 1Department of Clinical Therapeutics, University of Athens School of Medicine, Greece.

Hematology/Oncology Clinics of North America
|January 8, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece.

ESMO gastrointestinal oncology·2026
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

Seminars in hematology·2023
Same author

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.

Seminars in hematology·2023
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Waldenström's macroglobulinemia (WM) is a rare lymphoma producing IgM. Treatment involves chemotherapy and plasmapheresis, with nucleoside analogues effective for resistant cases.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström's macroglobulinemia (WM) is a rare, low-grade lymphoplasmacytic lymphoma.
  • Characterized by the overproduction of monoclonal immunoglobulin M (IgM).
  • Clinical features stem from tumor infiltration, IgM levels, and IgM deposition.

Purpose of the Study:

  • To outline the clinical manifestations and management strategies for Waldenström's macroglobulinemia.
  • To discuss current and emerging treatment options for WM patients.

Main Methods:

  • Review of clinical manifestations related to tumor burden and IgM properties.
  • Discussion of treatment modalities including chemotherapy, plasmapheresis, and novel therapies.
  • Evaluation of treatment efficacy based on patient response and survival rates.

Related Experiment Videos

Main Results:

  • Standard treatment with oral chlorambucil yields responses in over 50% of patients, with a median survival of approximately 5 years.
  • Nucleoside analogues (cladribine, fludarabine) show high efficacy in previously untreated patients and those resistant to alkylating agents.
  • Emerging treatments include high-dose therapy with stem-cell support and anti-CD20 monoclonal antibodies.

Conclusions:

  • Asymptomatic WM patients require monitoring without immediate treatment.
  • Chemotherapy and plasmapheresis are mainstays for managing symptomatic WM.
  • Nucleoside analogues and newer approaches offer improved outcomes for WM patients, particularly those with refractory disease.